Samlyn Capital’s Idexx Laboratories IDXX Stock Holding History

Samlyn Capital’s Portfolio IDXX Stock Details IDXX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-153,731	Closed	-$28.6M	–	119
2018 Q4	$28.6M	Buy	+153,731	New	+$31.5M	0.68%	46

Other funds holding IDXX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fundsmith LLP London, United Kingdom $13.6B AUM 7.6% 1-Year Est. Return

BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Samlyn Capital's IDXX Position: Q1 2019 in Review

Samlyn Capital sold out of Idexx Laboratories (IDXX) in Q1 2019, closing a stake of 153,731 shares — an estimated $28.6M sold.

Samlyn Capital first reported a position in IDXX in Q4 2018 and held it in 1 quarter. The position peaked at $28.6M in Q4 2018. 685 funds tracked by Wall St. Rank hold IDXX as of Q1 2019.

Samlyn Capital reported no remaining Idexx Laboratories position as of Q1 2019 after selling out during the quarter.
Samlyn Capital sold 153,731 Idexx Laboratories shares in Q1 2019, an estimated $28.6M.
Samlyn Capital first reported a position in Idexx Laboratories in Q4 2018 and held it in 1 quarter.
Samlyn Capital's Idexx Laboratories position peaked at $28.6M in Q4 2018.
685 funds tracked by Wall St. Rank held Idexx Laboratories as of Q1 2019.

Based on Samlyn Capital's 13F filing for Q1 2019, filed 15 May 2019.